Related Experiment Video

Updated: May 29, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Management of coronary artery disease in end-stage renal disease

John K Roberts1, Uptal D Patel

  • 1Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Seminars in Dialysis
|September 13, 2011
PubMed

Insights

For patients with end-stage renal disease and coronary artery disease, the best revascularization strategy remains unclear. Evidence suggests benefits from procedures like coronary artery bypass grafting and percutaneous coronary intervention, but more data is needed.

Area of Science:

  • Cardiology
  • Nephrology
  • Interventional Cardiology

Background:

  • Coronary artery disease (CAD) is prevalent in patients with end-stage renal disease (ESRD).
  • Comparative effectiveness of revascularization strategies (coronary artery bypass grafting [CABG] vs. percutaneous coronary intervention [PCI]) in ESRD patients is not well-defined.
  • Limited clinical trial data exists for this high-risk population.

Observation:

  • Non-randomized studies suggest ESRD patients may benefit significantly from coronary revascularization.
  • General population data is often extrapolated for treatment decisions in ESRD patients.
  • Individual patient circumstances influencing treatment choices are not always captured in existing studies.

Findings:

  • The optimal choice between CABG and PCI for ESRD patients with CAD requires careful consideration of limited evidence.
  • Existing evidence highlights potential benefits but lacks definitive comparative data.
  • Treatment decisions necessitate balancing available evidence with individual patient factors.

Implications:

  • Further research is crucial to establish evidence-based guidelines for revascularization in ESRD patients.
  • Clinicians must carefully weigh risks and benefits, considering individual patient contexts.
  • Improved understanding can lead to more personalized and effective treatment strategies for this vulnerable population.

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...